[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337000-105":59,"doc-detail-337000-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-idh-inhibitors-in-idh-mutated-cancers-a-systematic-review-and-meta-analysis-of-4-randomized-controlled-trials","Efficacy and safety of IDH inhibitors in IDH-mutated cancers - a systematic review and meta-analysis of 4 randomized controlled trials","","Meta-analysis assessing the efficacy and safety of isocitrate dehydrogenase (IDH) inhibitors for IDH-mutated cancers. Searches across PubMed, EMBASE, and Cochrane Library identified randomized controlled trials, and effect sizes were pooled using RevMan 5.4 with odds ratios or weighted mean differences at 95% confidence intervals. Four trials (751 patients) were included. Overall survival and treatment-related adverse events were not significantly different, while progression-free survival, objective response rate, and disease control rate were improved with IDH inhibitors. Adverse-event incidence was comparable to conventional therapy, though further trials are needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-idh-inhibitors-in-idh-mutated-cancers-a-systematic-review-and-meta-analysis-of-4-randomized-controlled-trials/337000/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-idh-inhibitors-in-idh-mutated-cancers-a-systematic-review-and-meta-analysis-of-4-randomized-controlled-trials/337000.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this systematic review and meta-analysis?","Question",{"text":112,"@type":113},"To evaluate the efficacy and safety of IDH inhibitors in cancers with IDH mutations by pooling results from randomized controlled trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and methods were used to collect and analyze evidence?",{"text":117,"@type":113},"PubMed, EMBASE, and Cochrane Library were searched, and meta-analysis was conducted using RevMan 5.4 to calculate odds ratios or weighted mean differences with 95% confidence intervals.",{"name":119,"@type":110,"acceptedAnswer":120},"What benefits and risks were observed for IDH inhibitors compared with control treatment?",{"text":121,"@type":113},"No significant difference was found for overall survival or treatment-related adverse events, while progression-free survival, objective response rate, and disease control rate were significantly higher in the IDH inhibitor group. Severe and overall adverse-event incidence were not significantly different either.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337000,1790118556,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cai etal. World Journal of Surgical Oncology (2024) 22:295  \n[https://doi.org/10.1186/s12957-024-03579-z](https://doi.org/10.1186/s12957-024-03579-z)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nEfficacy and safety of IDH inhibitors  \nin IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials  \nZelin Cai 1†, Huiting Yang 1†, Zhuoran Yu3, Jingyang Su2, Jie Zhang3, Zhifeng Ye4, Keke Hu4, Ting Huang4* and Heran Zhou4*  \nAbstract  \nBackground Isocitrate dehydrogenase (IDH) inhibitors have shown great promise in the treatment of cancers with IDH mutations. There have been numerous clinical trials conducted on IDH inhibitors, and to evaluate their efficacy and safety, we aim to perform a meta-analysis.  \nMethods To gather data on the efficacy and safety of IDH inhibitors for IDH-mutated cancers, we systematically searched through databases including PubMed, EMBASE, and Cochrane Library. Using RevMan5 .4, we performed a meta-analysis and calculated the odds ratio (OR) or weighted mean difference (WMD) with a 95% confidence interval (95%CI) . The parameters considered were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAEs), and TRAEs ≥ 3.  \nResults This meta-analysis included four studies, involving a total of 751 patients. According to the analysis, there was no significant difference in overall survival, treatment-related adverse events, and severe treatment-related adverse events between the experimental group (receiving IDH inhibitors) and the control group. However, the progressionfree survival, objective response rate, and disease control rate in the experimental group were significantly higher than those in the control group.  \nConclusion The overall efficacy of IDH inhibitors in treating cancers with IDH mutations is superior to that of conventional medical therapy, potentially providing more clinical benefits to patients. The incidence of adverse events was not significantly different from conventional medical therapy. Therefore, IDH inhibitors should be considered asthe preferred choice for treating cancers with IDH mutations. However, further randomized controlled clinical trials are still required for verification.  \n†Zelin Cai and Huiting Yang contributed equally to this work and share first authorship.  \n*Correspondence:  \nTing Huang [huangtin100@sohu.com](huangtin100@sohu.com)[ ](huangtin100@sohu.com)Heran Zhou [290829031@qq.com](290829031@qq.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nCai et al. World Journal of Surgical Oncology (2024) 22:295 Page 2 of 10  \nKeywords Isocitrate dehydrogenase, Safety, Efficacy, Inhibitor, Meta-analysis  \nIntroduction  \nThe isocitrate dehydrogenase (IDH) gene spike was initially discovered in certain types of brain tumors, such as astro","cbCaifCuMV0Au1wu","https://ap.wps.com/l/cbCaifCuMV0Au1wu","pdf",2184895,"English","# Introduction\n## IDH mutations and tumor biology\n## Rationale for IDH inhibitor targeted therapy\n# Methods\n## Literature search strategy\n## Outcome measures and effect size calculation\n# Results\n## Included studies and patient population\n## Survival and response outcomes\n## Treatment-related adverse events\n# Conclusion\n## Overall efficacy and safety considerations\n## Need for further randomized trials","[{\"question\":\"What is the purpose of this systematic review and meta-analysis?\",\"answer\":\"To evaluate the efficacy and safety of IDH inhibitors in cancers with IDH mutations by pooling results from randomized controlled trials.\"},{\"question\":\"Which databases and methods were used to collect and analyze evidence?\",\"answer\":\"PubMed, EMBASE, and Cochrane Library were searched, and meta-analysis was conducted using RevMan 5.4 to calculate odds ratios or weighted mean differences with 95% confidence intervals.\"},{\"question\":\"What benefits and risks were observed for IDH inhibitors compared with control treatment?\",\"answer\":\"No significant difference was found for overall survival or treatment-related adverse events, while progression-free survival, objective response rate, and disease control rate were significantly higher in the IDH inhibitor group. Severe and overall adverse-event incidence were not significantly different either.\"}]","Efficacy and safety of IDH inhibitors in IDH-mutated cancers - a systematic review and meta-analysis of 4 randomized controlled trials | PDF",1790017353,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2cd143731325fadf81e19885c96866b.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c9e8e1713865d70c2233c2c40667328.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4ed4bf8d8bdc168b5cc595508243ca8.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/386734042652a459527d16a5a174ecc5.webp",980,1306]